Ahmed F (2010) Insulin glargine and the risk of cancer. Cardiovasc J Afr 21(1):49

PubMed  PubMed Central  Google Scholar 

Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M et al (2022) Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast 66:15–23

Article  PubMed  PubMed Central  Google Scholar 

Baricevic I, Jones DR, Roberts DL, Lutzen A, Lundby A, Worm J et al (2015) A framework for the in vitro evaluation of cancer-relevant molecular characteristics and mitogenic potency of insulin analogues. Carcinogenesis 36(9):1040–50

Article  CAS  PubMed  PubMed Central  Google Scholar 

Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ et al (2019) Estimation of global insulin use for type 2 diabetes, 2018-30: a microsimulation analysis. Lancet Diabetes Endocrinol 7(1):25–33

Article  PubMed  Google Scholar 

Belfiore A, Malaguarnera R (2011) Insulin receptor and cancer. Endocr Relat Cancer 18(4):R125–R147

Article  CAS  PubMed  Google Scholar 

Biello F, Platini F, D’Avanzo F, Cattrini C, Mennitto A, Genestroni S et al (2021) Insulin/IGF axis in breast cancer: clinical evidence and translational insights. Biomolecules 11(1):125

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buse JB, Davies MJ, Frier BM, Philis-Tsimikas A (2021) 100 years on: the impact of the discovery of insulin on clinical outcomes. BMJ Open Diabetes Res Care 9(1):e002373

Article  PubMed  PubMed Central  Google Scholar 

But A, De Bruin ML, Bazelier MT, Hjellvik V, Andersen M, Auvinen A et al (2017) Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. Diabetologia 60(9):1691–1703

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chappell J, Leitner JW, Solomon S, Golovchenko I, Goalstone ML, Draznin B (2001) Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. J Biol Chem 276(41):38023–38028

Article  CAS  PubMed  Google Scholar 

Chen H, Zhang ZW, Guo Y, Wang Y, Liu Y, Luo N et al (2012) <article-title update="added">Ani-survivin DNAzymes Inhibit Cell Proliferation and Migration in Breast Cancer Cell Line MCF-7. J BUON 17(4):658–62

PubMed  Google Scholar 

Disrupting Insulin and IGF Receptor Function in Cancer - PMC [cited 2023 Nov 23]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7827299/

Djiogue S, Kamdje AHN, Vecchio L, Kipanyula MJ, Farahna M, Aldebasi Y et al (2013) Insulin resistance and cancer: the role of insulin and IGFs. Endocrine-Relat Cancer 20(1):R1-17

Article  CAS  Google Scholar 

Galal MA, Alouch SS, Alsultan BS, Dahman H, Alyabis NA, Alammar SA et al (2023) Insulin receptor isoforms and insulin growth factor-like receptors: implications in cell signaling, carcinogenesis, and chemoresistance. Int J Mol Sci 24(19):15006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallagher EJ, LeRoith D (2010) The proliferating role of insulin and insulin-like growth factors in cancer. Trends Endocrinol Metab 21(10):610–618

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z et al (2013) Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes 62(10):3553–3560

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA et al (2010) Diabetes and cancer. Diabetes Care 33(7):1674–85

Article  PubMed  PubMed Central  Google Scholar 

Hansen BF, Kurtzhals P, Jensen AB, Dejgaard A, Russell-Jones D (2011) Insulin X10 revisited: a super-mitogenic insulin analogue. Diabetologia 54(9):2226–2231

Article  CAS  PubMed  Google Scholar 

Heuson JC, Legros N, Heimann R (1972) Influence of insulin administration on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in intact, oophorectomized, and hypophysectomized rats1. Cancer Res 32(2):233–238

CAS  PubMed  Google Scholar 

Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, Svendsen AM et al (2012) Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocrine-Relat Cancer 1;19(4):557–74

Article  Google Scholar 

Krajnak S, Loewe A, Battista MJ, Hasenburg A, Heimes AS, Schmidt M et al (2021) The impact of insulin on low-dose metronomic vinorelbine and mafosfamide in breast cancer cells. Anticancer Res 41(3):1243–1250

Article  CAS  PubMed  Google Scholar 

Kurtzhals P, Schäffer L, Sørensen A, Kristensen C, Jonassen I, Schmid C et al (2000) Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49(6):999–1005

Article  CAS  PubMed  Google Scholar 

Lega IC, Austin PC, Fischer HD, Fung K, Krzyzanowska MK, Amir E et al (2018) The impact of diabetes on breast cancer treatments and outcomes: a population-based study. Diabetes Care 41(4):755–761

Article  PubMed  Google Scholar 

Liefvendahl E, Arnqvist HJ (2008) Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res 40(06):369–374

Article  CAS  PubMed  Google Scholar 

Lind M, Fahlén M, Eliasson B, Odén A (2012) The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Prim Care Diabetes 6(1):53–59

Article  PubMed  Google Scholar 

Liu S, Li Y, Pan Q, Wei J, Liang Y, Fu Y et al (1986) Effect of insulin glargine and human insulin on proliferation of a human breast cancer cell line MDA-MB-231. Chin Pharmacol Bull.

Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G (2011) Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation. Acta Oncol 50(5):685–693

Article  PubMed  Google Scholar 

Lofterød T, Frydenberg H, Flote V, Eggen AE, McTiernan A, Mortensen ES et al (2020) Exploring the effects of lifestyle on breast cancer risk, age at diagnosis, and survival: the EBBA-Life study. Breast Cancer Res Treat 182(1):215–227

Article  PubMed  PubMed Central  Google Scholar 

Lundby A, Bolvig P, Hegelund AC, Hansen BF, Worm J, Lützen A et al (2015) Surface-expressed insulin receptors as well as IGF‐I receptors both contribute to the mitogenic effects of human insulin and its analogues. J Appl Toxicol 35(7):842–50

Article  CAS  PubMed  Google Scholar 

Malaguarnera R, Belfiore A (2011) The insulin receptor: a new target for cancer therapy. Front Endocrinol (Lausanne) 2:93

Article  PubMed  PubMed Central  Google Scholar 

Mannucci E (2012) Insulin therapy and cancer in type 2 diabetes. Int Sch Res Not 2012:e240634

Google Scholar 

Mannucci E, Monami M, Balzi D, Cresci B, Pala L, Melani C et al (2010) Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care 33(9):1997–2003

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mayer D, Chantelau E (2010) Treatment with insulin glargine (Lantus®) increases the proliferative potency of the serum of patients with type-1 diabetes: a pilot study on MCF-7 breast cancer cells. Arch Physiol Biochem 116(2):73–78

Article  CAS  PubMed  Google Scholar 

Mayer D, Shukla A, Enzmann H (2008) Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 114(1):38–44

Article  CAS  PubMed  Google Scholar 

Milazzo G, Sciacca L, Papa V, Goldfine ID, Vigneri R (1997) ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor. Mol Carcinog 18(1):19–25